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Abstract
Background: Standard lymphadenectomy during pancreaticoduodenectomy (PD) for peri-ampullary
cancer does not include the routine removal of para-aortic lymph nodes (PALN) (station 16, according
to the JPS staging system). The aim of this study was to report the incidence and the prognostic value
of PALN metastases in patients undergoing PD for peri-ampullary cancer.
Materials and methods: One hundred thirty-five consecutive patients who underwent PD and PALN
dissection for peri-ampullary cancer were prospectively evaluated. The relationship between clinico-
pathological factors, including PALN metastases and survival was evaluated at univariate and multivari-
ate analysis.
Results: PALN metastases (N16+) were found in 11.1% of cases. At univariate analysis, R1 resection,
metastatic nodes different from para aortic (N1) and N16+ significantly affected patients’ prognosis.
Compared with N16+, the median overall survival (OS) of N0 patients was significantly longer (32 ver-
sus 69 months, respectively; P < 0.05), whereas no difference was found between N16+ and N1
patients (32 versus 34 months, respectively) (P > 0.05). At multivariate analysis, only R1 resection
reached statistical significance and was confirmed an independent prognostic factor.
Conclusions: Neoplastic involvement of PALN in peri-ampullary cancer is frequent and, so, their
removal during PD could be justified. Moreover, PALN metastases should be not considered an abso-
lute contraindication to radical surgery.
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Introduction
Pancreaticoduodenectomy (PD) is the treatment of choice of
patients affected by peri-ampullary cancer.1 The extent of the
cancer to the regional lymph nodes is a powerful prognostic
factor after resection independently from cancer histology.2 For
this reason, lymphadenectomy is considered a crucial step of
PD for cancer.3,4 In 2014, a consensus meeting of the Interna-
tional Study Group on Pancreatic Surgery (ISGPS) in Verona5
on the definition and the prognostic role of lymphadenectomy
during PD for cancer stated that: (i) the use of the nomencla-
ture for nodal stations based on the classification of the Japa-
nese Pancreas Society6 is recommended; (ii) an extended
lymphadenectomy does not improve the oncological outcome
of patients and should not be associated with PD for cancer;
(iii) lymphadenectomy should include the removal of the hep-
atoduodenal ligament nodes (stations 5, 6, 12b1, 12b2, 12c),
nodes along the hepatic artery (station 8a), the posterior sur-
face of the pancreatic head (station 13a and 13b), the superior
mesenteric artery (14a right lateral side, 14b right lateral side)
and nodes of the anterior surface of the pancreatic head (sta-
tions 17a and 17b).5 As no consensus among experts was
reached on the role of para-aortic lymph nodes (PALN), the
Verona meeting did not point out any statement on this argu-
ment. Therefore, a standard lymphadenectomy, as defined by
the ISGPS, does not include the removal of para-aortic nodes
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along the posterior side of the pancreas, between the aorta and
the inferior vena cava (station 16).5 Based on the available
evidence on this issue, the following questions about para-
aortic nodes are still unsolved:
1 Which is the real incidence of neoplastic involvement of sta-
tion 16 in peri-ampullary cancers?
2 Is PALN involvement a prognostic factor after PD for peri-
ampullary cancer?
3 Is the intra-operative evidence of the metastatic para-aortic
nodes at frozen section a contraindication in performing
PD?
The aim of this study was to report the results of a prospec-
tive evaluation on the incidence and the prognostic value of
PALN metastases in patients undergoing PD for peri-ampullary
cancer.
Patients and methods
Patients affected by peri-ampullary cancer that underwent PD
at the Campus Bio-Medico University of Rome between 2006
and 2014 were prospectively evaluated.
All PDs were performed with curative intent by a single
expert surgeon. A standard lymphadenectomy including the
removal of stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a
right lateral side, 14b right lateral side, 17a and 17 was rou-
tinely performed. Para-aortic nodal dissection including the
lymph nodes from the upper part of the celiac trunk to the
upper part of the origin of the inferior mesenteric artery was
routinely performed. In case of vascular neoplastic infiltration,
a vascular resection was performed.
One hundred thirty-five consecutive patients underwent PD
for peri-ampullary cancer during the study period. The cohort
of patients was composed of 80 males (59.3%) and 55 females
(40.7%). One-hundred twenty-one patients (90%) underwent
surgery as first approach to the disease; in 14 patients (10%)
neoadjuvant treatment was performed. Neoadjuvant treatment
(radio-chemotherapy) was performed only in case of locally
advanced/unresectable disease, confirmed with a pre-operative
computed tomography scan. The pylorus was preserved in
72.6% of cases (Table 1).
The incidence of PALN metastases was evaluated in all cases.
We divided the entire cohort into three groups: (i) patients with-
out nodal involvement (N0 group); (ii) patients with lymph
nodal neoplastic involvement, other than the para-aortic station
(N1 group); and (iii) patients with para-aortic nodal metastases
(N16+). The following clinical-pathological factors were evalu-
ated in these groups: patient demographics, operative procedures,
access to neoadjuvant/adjuvant treatments, tumour histology, T
and N stage, lymph-node ratio (LNR, i.e. the ratio between the
number of positive and harvested lymph nodes) and the resection
margin (RM) status. According to Royal College of Pathologist
guidelines,7 a surgical resection is defined R1 in the presence of a
distance between the tumour and each margin of less than 1 mm.
The follow-up was realized according to a standardized sched-
ule at regular intervals up to 5 years after surgery. The median
follow-up was 41 months (2–135). No drop out at follow-up
was observed. The overall survival (OS) was calculated from the
date of surgery to the date of last follow-up/death. Differences in
OS between the N0, N1 and N16+ groups were evaluated.
Statistical analysis
Differences in clinical-pathological parameters between nega-
tive and positive nodes where assessed using the chi-square test
and one-way ANOVA. Survival data was presented using Kaplan–
Meier survivor function. Differences in survivals were per-
formed using the log-rank test of equality. The Cox propor-
tional hazards model was used for multivariate analysis of
survival to determine the significance of the various predictive
variables that were found to be significant in univariate analy-
sis. All analyses were undertaken with Stata Statistical Software
(Stata Corporation LP, College Station, Texas, USA) and a P-
value < 0.05 was considered significant.
Table 1 Clinical and pathological data of the 135 patients
No. of patients (%)
Gender
Male 80 (59.3)
Female 55 (40.7)
Neoadjuvant treatments 14 (10.4)
Type of resection
Whipple 37 (27.4)
Pylorus-preserving PD (PPPD) 98 (72.6)
Tumour histology
PDAC 86 (63.7)
Ampullary adenocarcinoma 31 (23.0)
Distal bile duct carcinoma 18 (13.3)
T status
T1 5 (3.7)
T2 18 (13.3)
T3 98 (72.6)
T4 14 (10.4)
N status
N0 46 (34.1)
N1 89 (65.9)
R status
R0 79 (58.5)
R1 56 (41.5)
M+ (para-aortocaval nodes) 15 (11.1)
Harvested lymph nodes (mean, range) 30 (5–75)
LNR (mean) 0,11
Adjuvant treatments 85 (63.0)
PDAC, pancreatic ductal adenocarcinoma; LNR, lymph-node ratio.
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Results
Clinical and pathological data of 135 evaluated patients are
reported in Table 1. Final histological report described a pan-
creatic ductal adenocarcinoma (PDAC) in 63.7% of cases, an
ampullary adenocarcinoma in 23% of cases and a bile duct
carcinoma in 13.3% of cases. In more than 80% of cases, the
tumour was locally extended (stage T3 or T4). A microscopic
residual tumour (R1) was present in 41,5% of cases. The mean
number of harvested lymph nodes was 30 (5–75), and the
mean LNR was 0.11. The overall rate of nodal metastases other
than para-aortic (N1) was 65.9%. The overall rate of para-aor-
tic nodal metastases was 11.1%. Sensitivity and specificity of
the frozen section in the detection of para-aortic nodal metas-
tases were 83.3% and 100%, respectively.
In Table 2, clinical-pathological data of N0, N1 and N16+
patients are reported. The three groups did not significantly
differ in terms of gender, type of resection and tumour his-
tology. Neoadjuvant chemoradiation was more frequently per-
formed in N16+ patients (27%) compared with N0 (13%) (P
< 0.05) and N1 (5%) patients (P < 0.05). A significant corre-
lation between tumour size and N status was also observed;
compared with N0, N1 and N16+ patients were more fre-
quently affected by T3/T4 tumours (P < 0.05); in contrast, no
differences in terms of T status were found between N1 and
N16+ patients (P = NS). Furthermore, R1 resection was more
frequently associated with N1 and N16+ compared with N0
cases (R1-N16+: 55% versus R1-N0: 13%, P < 0.05; R1-N1:
60% versus R1-N0: 13%, P < 0.01); no differences in terms
of R1 resection were found between N1 and N16+ patients
(R1-N16+: 55% versus R1-N1: 60%, P = NS). The number of
harvested lymph nodes was significantly related to N status
with N0 patients statistically associated with a smaller number
of harvested lymph nodes (mean 22.6) compared with N1
(mean 32.3) (P < 0.01) and N16+ patients (mean 36.4) (P <
0.05). No differences were found in terms of the mean num-
ber of harvested lymph nodes between N1 and N16+ patients
(32.3 and 36.4, respectively; P = NS). However, the mean
LNR was significantly higher in N16+ (0.27) compared with
N1 patients (0.13) (P < 0.05). Compared with N0, N1 and
N16+ patients underwent more frequently adjuvant treatment
[N1: 69% versus N0: 44% (P < 0.05); N16+: 87% versus N0:
44%,
(P < 0.05)], whereas no differences were found between the
N16+ and N1 groups (N16+: 87% versus N1: 69%; P = NS).
The median OS of the entire cohort was 41 months. Com-
pared with N16+, the median OS of N0 patients was signifi-
cantly longer (N16+: 32 months; N0: 69 months; P < 0.05)
(Fig. 1 and Table 3). Comparison in terms of the median OS
between N1 and N0 patients showed that N1 patients were
affected by a shorter median OS (34 versus 69 months; HR
1.82) (P < 0.05) (Table 3). Conversely, the comparison of the
median OS between N16+ and N1 patients did not show
Table 2 Comparison between N16+ and N16- patients (clinical-
pathological data; chi-squared from proportions, one-way ANOVA
for continuous data)
N0 Group
(45 cases)
N (%)
N1 group
(75 cases)
N (%)
N16+ group
(15 cases)
N (%)
P
Gender
Male 27 (60) 48 (64) 5 (33) N0 versus
N1: NS
N0 versus
N16+: NS
N1 versus
N16+: NS
Female 18 (40) 27 (36) 10 (67)
Neoadjuvant
treatments
6 (13) 5 (5) 4 (27) N0 versus
N1: NS
N0 versus
N16+: NS
N1 versus
N16+: < 0.05
Type of resection
Whipple 9 (20) 24 (32) 4 (27) N0 versus
N1: NS
N0 versus
N16+: NS
N1 versus
N16+: NS
PPPD 36 (80) 51 (68) 11 (73)
Tumour histology
PDAC 26 (58) 48 (64) 12 (80) N0 versus
N1: NS
N0 versus
N16+: NS
N1 versus
N16+: NS
Ampullary
adenocarcinoma
13 (29) 17 (23) 1 (7)
Distal bile
duct carcinoma
6 (13) 10 (13) 2 (13)
T status
T1 5 (11) 0 (0) 0 (0) N0 versus
N1: <0.01
N0 versus
N16+: <0.05
N1 versus
N16+: NS
T2 13 (29) 5 (7) 0 (0)
T3 23 (51) 61 (81) 14 (93)
T4 4 (9) 9 (12) 1 (7)
R status
R0 39 (87) 34 (45) 6 (40) N0 versus
N1: <0.01
N0 versus
N16+: <0.01
N1 versus
N16+: NS
R1 6 (13) 41 (55) 4 (60)
Harvested lymph
nodes
(mean, CI 95%)
22 (19–27) 32 (29–36) 36 (24–49) N0 versus
N1: <0.01
N0 versus
N16+: <0.01
N1 versus
N16+: NS
LNR
(mean, CI 95%)
0 13 (11–16) 27 (18–36) N1 versus
N16+: <0.01
Adjuvant
treatments
20 (44) 52 (69) 13 (87) N0 versus
N1: <0.01
N0 versus
N16+: <0.01
N1 versus
N16+: NS
NS, not significant; PPPD, pylorus-preserving PD; PDAC, pancreatic duc-
tal adenocarcinoma; LNR, lymph-node ratio; CI, confidence interval.
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significant differences (32 versus 34 months, respectively)
(P = NS) (Fig. 2 and Table 3).
Survival analysis was also performed in the subgroup of
patients affected by PDAC (Table 4). The median OS was sig-
nificantly better in N0 patients (71 months) compared with
N1 (38 months, HR 1.8, P < 0.05) and to N16+ (18 months,
HR 1.82, P < 0.05) patients (Fig. 3 and Table 4). No difference
in terms of median OS was found between N1 and N16+
patients (38 versus 18 months, P > 0.05) (Fig. 4 and Table 4).
At univariate analysis, an R1 resection, N1 and N16+ signifi-
cantly affected the prognosis of patients (HR 2.49, 1.79 and
3.47, respectively) (Table 5). At multivariate analysis, only an
R1 resection reached the statistical significance (Table 5).
Discussion
The ’ideal‘ lymphadenectomy associated with PD for cancer is
still an argument of debate. Although the lymph nodal status
of resected peri-ampullary cancer patients is considered a rele-
vant predictor of survival, four randomized controlled and a
meta-analysis did not support an improved clinical outcome of
an ’extended‘ compared with a ’standard‘ nodal dissection.8–12
This evidence was confirmed in 2014 by the final statements of
the International Study Group of Pancreatic Surgery (ISGPS)
on this topic.5 At the Verona meeting, the role of PALN (sta-
tions 16) in surgically resected peri-ampullary cancer patients
and the surgical approach to be adopted was also discussed.
However, the discussion revealed that only half of the involved
surgeons routinely perform a station 16 nodal dissection and
that no consensus could be reached between the participating
pancreatic surgeons. Consequently, no final recommendations
on this issue were subscribed.
Several studies on lymphatic drainage pathways have shown
that PALN play a key role in the lymphatic drainage of the
pancreatic head.13,14 Lymphatic drainage of peri-ampullary
cancers (independently from the histological origin of the
tumour) takes place either from the anterior (station 17) as
well the posterior (station 13) surface of the pancreatic head.
From the pancreatic head, the lymphatic drainage continues
towards the lymph nodes along the superior mesenteric artery
(station 14) and to the para-aortic station (station 16).12,13
Other anatomical studies showed that in a small percentage of
cases, the lymphatic drainage directly merges into the nodal
Figure 1 Kaplan–Meier survival curves for the entire cohort
[median overall survival (OS) for N0 and N16+ patients]
Table 3 Differences in the survival median months and hazard
ratio in patients without lymph nodes involvement (N0), with lymph
nodes involvement different from para-aortic lymph nodes (N1)
and with para-aortic lymph-node involvement (N16+)
Group N Median
survival
(CI 95%)
in months
Hazard ratio
(CI 95%)
P
No lymph-nodes
involvement (N0)
44 69 (38–101) 1
Para-aortic lymph-nodes
involvement (N16+)
15 32 (7–32) 1.82 (1.08–3.05) <0.05
No lymph nodes
involvement (N0)
44 69 (38–101) 1
Lymph nodes
involvement different
from para-aortic
lymph nodes (N1)
75 34 (20–63) 1.80 (1.02–3.17) <0.05
Lymph nodes
involvement different
from para-aortic
lymph nodes (N1)
75 34 (20–63) 1
Para-aortic lymph
nodes involvement
(N16+)
15 32 (7–32) 1.96 (0.79–4.80) n.s.
Figure 2 Kaplan–Meier survival curves for the entire cohort
[median overall survival (OS) for N1 and N16+ patients]
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stations along the proper hepatic artery (station 8) before
reaching station 16 via the lymph nodes of the celiac axis (sta-
tion 7).15
In spite of the major role played by the para-aortic stations
in lymphatic drainage of peri-ampullary cancers, no clear data
regarding the incidence of neoplastic involvement of nodal sta-
tion 16 in patients undergoing PD for cancer are reported in
the literature. This figure was the primary aim of the present
study. Our results showed that 11.1% of our cases were
Table 4 Differences in survival in subgroup of pancreatic cancer
patients median months and hazard ratio in patients without lymph
nodes involvement (N0), with lymph nodes involvement different
from para-aortic lymph nodes (N1) and with para-aortic lymph
nodes involvement (N16+)
Group N Median
survival
(CI 95%)
in months
Hazard ratio
(CI 95%)
P
No lymph nodes
involvement (N0)
25 71 (24–144) 1
Lymph nodes
involvement different
from para-aortic
lymph nodes (N1)
48 38 (20–63) 1.80 (1.02–3.17) <0.05
No lymph nodes
involvement (N0)
25 71 (24–144) 1
Para-aortic lymph
nodes involvement
(N16+)
12 18 (6–18) 1.82 (1.08–3.05) <0.05
Lymph nodes
involvement
different from
para-aortic
lymph nodes (N1)
48 38 (20–63) 1
Para-aortic
lymph nodes
involvement (N16+)
12 18 (6–18) 1.96 (0.79–4.80) n.s.
CI, confidence interval.
Figure 3 Kaplan–Meier survival curves in subgroup of pancreatic
ductal adenocarcinoma (PDAC) patients [median overall survival
(OS) for N0 and N16+ patients]
Figure 4 Kaplan–Meier survival curves in subgroup of pancreatic
ductal adenocarcinoma (PDAC) patients [median overall survival
(OS) for N1 and N16+ patients]
Table 5 Univariate and multivariate survival analysis of prognostic
factors after resection for peri-ampullary cancer
Factors Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
T status
0 1
1 1.18 0.82–1.69 n.s.
Lymph nodes metastasis
N0 1
N1 1.79 1.01–3.16 <0.05 1.47 0.8–2.6 n.s.
N16+ 3.47 1.32–9.09 <0.01 2.41 0.8–6.6 n.s.
Surgical margin
R0 1
R1 2.49 1.41–4.38 <0.01 2.07 1.1–3.7 <0.05
Tumour histology
PDAC 1
Ampullary
adenocarcinoma
1.12 0.60–2.00 n.s.
Distal bile
duct carcinoma
1.72 0.82–3.63 n.s.
Adjuvant treatment
No 1
Yes 1.17 0.69–1.99 n.s.
HR, hazard ratio; CI, confidence interval; PDAC, pancreatic ductal ade-
nocarcinoma.
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affected by para-aortic nodal metastases. This result confirms
that PALN are a relevant site in the pathway of peri-ampullary
cancer. These results are confirmed by others studies that
report a 10–25% incidence of station 16 involvement
(Table 6).16–24 Remarkably, this incidence is comparable to the
rate of lymph nodes metastases of the hepatoduodenal liga-
ment, routinely excised according to the final recommenda-
tions of the ISGPS consensus meeting.5 A recent paper from
the Memorial Sloan-Kettering including 147 surgically resected
pancreatic head cancer patients, reported a 16% rate of neo-
plastic involvement of the hepatic artery lymph nodes (8a and
8p).25 Therefore, if the incidence of metastases affecting para-
aortic, hepato-duodenal ligament and hepatic artery lymph
nodes metastases is comparable, we should argue that a lym-
phadenectomy associated with PD for cancer should be system-
atically extended to station 16. Moreover, it is necessary to
clarify that dissection of the para-aortic nodes is not a complex
procedure (it can be easily performed immediately after the
Kocher’s manoeuvre), and it is not associated with increased
morbidity: in our series, no serious adverse event strictly
related to the removal of station 16 was observed.
The kind of para-aortic nodal dissection to be performed is
another crucial point. In fact, according to JPS, station 16 can
be divided into four subgroups of lymph nodes, from cranial
to caudal areas: (i) station 16a1: lymph nodes located in the
area of the aortic hiatus (about 4–5 cm in width, surrounded
by the medial crus of the diaphragm); (ii) station 16a2: lymph
nodes located in the area from the uppermost part of the
origin of the celiac trunk to the lower margin of the left renal
vein; (iii) station b1: lymph nodes located in the area from the
lower margin of the left renal vein to the uppermost part of
the origin of the inferior mesenteric artery; and (iv) station
16b2: lymph nodes located in the area from the upper margin
of the origin of the inferior mesenteric artery to the aortic
bifurcation. Therefore, PALN dissection should include the
removal of all four nodal groups. Interestingly, the Verona
consensus meeting discussed (without reaching experts’ com-
mon opinion) the opportunity to remove only station 16b1.5
In contrast, JPS recommendations report that PD should be
associated with the removal of sub-stations 16a2 and 16b.6
Unfortunately, most of the studies reporting a para-aortic lym-
phadenectomy during PD (Table 6) do not precisely report
what kind of para-aortic nodal dissection is reported15,16,18,21–
23 or, if reported, it differs from study to study.19,20 Based on
these evidence, it can be concluded that the results in terms of
peri-operative and the oncological outcome of a complete sta-
tion 16 nodal dissection associated with PD for cancer has
never been reported. Conversely, based on the description
given by Authors in the considered articles, we can affirm that
what surgeons performed is a nodal sampling rather than a
systematic para-aortic lymphadenectomy. Obviously, these
anatomical aspects must be taken into account, as they can sig-
Table 6 Comparison of studies evaluating the incidence and the prognostic significance of neoplastic involvement of para-aortic lymph
nodes
Author, year of
publication
Tumour histology Type of
para-aortic
dissection
No. of metastatic
para-aortic
nodes (%)
Survival Strategy recommended
Kayahara M, 199815 PDAC Not reported 18 (18.2) Not evaluable Not reported
Yoshida T, 199821 Cholangiocarcinoma Not reported 5 (25) Not reported Not reported
Yoshida T, 200423 Peri-ampullary tumours Not reported 15 (15) 1-year survival: 33% Contraindication to PD
2-year survival: 27%
3-year survival: 0%
Mean survival 14.7 months
Shimada K, 200616 PDAC Not reported 27 (19.8) Median OS: 13 months Contraindication to PD
Doi R, 200717 PDAC 16a2 + 16b1 19 (14.3) Median OS: 5.1 months Contraindication to PD
1-year survival: 16%
Yamada S, 200918 PDAC Not reported 48 (8.9) Median OS: 8.0 months Indication to PD
Yamada S, 200922 PDAC Not reported 45 (13.4) Median OS: 7.8 months Not absolute
contraindication to PD
Murakami Y, 201120 Cholangiocarcinoma 16a2 + 16b1 17 (15) 5-year survival: 24% Indication to PD
Schwarz L, 201419 PDAC 16b1 17 (15.3) Median OS: 15.7 months Contraindication to PD
Median DFS: 8.4 months
Current study, 2015 Peri-ampullary
tumours and PDAC
16a2 + 16b1 15 (11.1) Mean OS (periampullary):
32 months
Indication to PD
Median OS (PDAC): 18
PDAC, pancreatic ductal adenocarcinoma; OS, overall survival.
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nificantly affect data regarding the real incidence and the prog-
nostic impact of para-aortic metastases.
The present study showed that each histotype is character-
ized by a specific attitude to metastasize into PALN. In fact,
we found that ampullary cancer is affected by the lowest inci-
dence of para-aortic involvement (3.2%) if compared with
pancreatic (13.9%) and distal common bile duct cancer
(11.1%) (Table 2). This result should be hopefully confirmed
by larger series of surgically resected peri-ampullary cancers.
The prognostic impact of the neoplastic involvement of the
para-aortic nodes and the surgical strategy to adopt are proba-
bly the most demanding problems to be solved. In fact, in the
literature some studies showed no difference in terms of sur-
vival between patients with or without metastatic PALN under-
going a resection,11,20 whereas others reported poorer survival
rates for patients with positive PALN.16,17,19,23 However, to our
best knowledge, there is no level I evidence concerning the
prognostic impact of metastatic para-aortic nodes after PD for
cancer (Table 6).15–23 Most of the studies considered only
patients affected by pancreatic cancer,15–19,22 others only by dis-
tal common bile duct cancer,20,21 and only one study consid-
ered patients affected by all peri-ampullary cancers.23
Moreover, the results of the studies in terms of the prognostic
impact of para-aortic nodes are discordant. Yoshida et al.23 first
retrospectively evaluated in 2004 101 patients that underwent
PD with curative intent for peri-ampullary cancer. The rate of
metastatic PALN was 15% (26% and 17% of pancreatic and
distal common bile duct cancer, respectively). Overall survival
resulted significantly longer for PDAC and common bile duct
cancer patients without PALN metastasis. According to these
results, the authors recommended the systematic execution of
para-aortic nodal sampling and, in case of positive frozen sec-
tion, to abandon radical surgery. These results were confirmed
by another three studies that analysed the prognostic impact of
metastatic PALN in patients that underwent PD for pancreatic
cancer.16,17,19,23 In summary, all the above-reported studies
confirmed that metastatic para-aortic nodes significantly affect
the prognosis and the authors’ conclusion, in case of intra-
operative evidence of metastatic station 16+ lymph nodes, was
that the surgical excision of the primitive tumour should be
abandoned. However, other studies18,20,22 showed different
results and stated different conclusions. Yamada et al. 22
showed that the overall survival of patients with para-aortic
metastases was significantly shorter if compared with negative
nodes patients in a series of 360 PDAC patients undergoing
PD. However, the comparison of survival data of resected
patients with para-aortic metastatic nodes and non-resected
patients for locally advanced and/or metastatic disease showed
a survival benefit for N16+ resected patients. For this reason,
the authors concluded that an intra-operative positive frozen
section of PALN should not be considered a contraindication
for radical surgery. A similar conclusion was stated by Mura-
kami et al.20 who reported a shorter overall survival in
patients with para-aortic lymph nodes metastases compared
with the survival of N0 patients in a series of 113 PD for dis-
tal cholangiocarcinoma. However, the authors also showed
that the overall survival of patients with PALN metastasis did
not differ from UICC N1 cases. The authors’ conclusion was
that PD should not be abandoned in the case of PALN
metastasis. Lastly, similar results was obtained by Schwarz
et al.20: the median OS and DFS in patients with regional
lymph node involvement only and in patients with both
regional and para-aortic node involvement were 21.0 versus
15.1 months (P = 0.110) and 12.7 versus 9.6 months (P =
0.120), respectively. The results of the present study seem to
support this conclusion. In our series, patients affected by
PALN metastases (N16+) were affected by a worse prognosis
if compared with N0 patients (Fig. 1). At univariate analysis,
both N1 and N16+ patients were found to be significant
prognostic factors. More interestingly, similarly to the results
of Murakami et al.,20 survival analysis of N1 and N16+
patients did not show significant differences between the two
groups (Fig. 2). The same results have been obtained consid-
ering only the subgroup of patients with PDAC (Figs 3 and
4), even if a difference in terms of OS between N16+ and N1
was greater in PDAC patients if compared with the entire
cohort. Probably, this result is as a result of a worse biologi-
cal behaviour of PDAC tumours if compared with other peri-
ampullary neoplasms. Larger series considering all peri-am-
pullary neoplasms and not only PDAC patients are needed to
confirm the prognostic role of para-aortic nodal metastases
for each histological type of periampullary tumour. These
results seem to confirm that the intra-operative evidence of
para-aortic nodal metastases should be considered as equiva-
lent to other regional lymph nodes metastases and that it
should not be considered an absolute contraindication for
radical surgery.
Conclusions
The results of our study clearly demonstrated that the inci-
dence of para-aortic lymph node metastasis during PD for
periampullary cancer is relevant (more than 10% of resected
cases) and for this reason we think that the removal of para-
aortic nodal station (station 16a2+16b1) could be justified.
Regarding the prognostic significance of metastatic para-aor-
tic nodal involvement, we found that the survival of patients
with para-aortic metastases seems to be comparable to that of
patients with other lymph nodes involvement. For this reason,
we concluded that at the moment the presence of para-aortic
nodal metastasis should be not considered an absolute
contraindication to radical surgery. Further studies with a lar-
ger cohort of patients are warranted.
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